HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502,...
Takeda
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation...
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot...
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK),...
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this...
Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP
Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour...
FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL
The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s...
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based...
Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...
Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio
Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO:...
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...
European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy
The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502)...
Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502)...
Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...
Takeda Ends Gene Therapy Collaboration with JCR Pharmaceuticals, Returns IP
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement...
Takeda’s Livtencity Receives NMPA Approval, a First in China for CMV Infection Treatment
Japanese pharmaceutical company Takeda (TYO: 4502) has received its first market approval from China’s National...
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its...
Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China
Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...